Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Not yet recruiting1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (50.0%)
Phase 42 (50.0%)

Trials by Status

completed350%
not_yet_recruiting117%
withdrawn117%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_3

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

NCT07114640
unknown

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

NCT05040984
completed

Predictors for Retreatement of OAB After DC Mirabegron

NCT04550702
withdrawnphase_4

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

NCT03695822
completedphase_4

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

NCT03558919
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07114640Phase 3

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Not Yet Recruiting
NCT05040984

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Unknown
NCT04550702

Predictors for Retreatement of OAB After DC Mirabegron

Completed
NCT03695822Phase 4

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Withdrawn
NCT03558919Phase 4

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Completed
NCT03059134Phase 3

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6